Try our mobile app

Published: 2023-03-21 07:26:27 ET
<<<  go to SY company page
EX-99.1 2 tm2310129d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2022 Financial Results

 

BEIJING, China, Mar. 21, 2023 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2022.

 

Fourth Quarter 2022 Financial Highlights

 

·Total revenues were RMB325.1 million (US$47.1 million1), compared to RMB449.5 million in the corresponding period of 2021, in line with our previous guidance.

 

·Net income attributable to So-Young International Inc. was RMB31.3 million (US$4.5 million), compared with net loss attributable to So-Young International Inc. of RMB27.7 million in the same period of 2021.

 

·Non-GAAP net income attributable to So-Young International Inc.2 was RMB38.8 million (US$5.6 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB62.9 million in the same period of 2021.

 

Fourth Quarter 2022 Operational Highlights

 

·Average mobile MAUs were 4.0 million, compared with 7.4 million in the fourth quarter of 2021.

 

·Number of paying medical service providers on So-Young’s platform was 4,274, compared with 5,327 in the fourth quarter of 2021.

 

·Number of medical service providers subscribing to information services on So-Young’s platform was 1,489, compared with 2,085 in the fourth quarter of 2021.

 

·Total number of purchasing users through reservation services was 120.4 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB370.2 million.

 

Fiscal Year 2022 Financial Highlights

 

·Total revenues were RMB1,257.9 million (US$182.4 million) in the full year 2022, a decrease of 25.7% from RMB1,692.5 million in the prior year.

 

·Net loss attributable to So-Young International Inc. was RMB65.6 million (US$9.5 million) in the full year 2022, compared with a net loss attributable to So-Young International Inc. of RMB8.4 million in the prior year.

 

·Non-GAAP net loss attributable to So-Young International Inc. was RMB22.2 million (US$3.2 million) in the full year 2022, compared with RMB139.5 million non-GAAP net income attributable to So-Young International Inc. in the prior year.

 

 

1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.8972 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 30, 2022.

 

2 Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So- Young International Inc. excluding share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

 

1

 

 

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “2022 is a remarkable year for all of us at So-Young. Despite multiple external headwinds, we have successfully stabilized our core businesses and substantially improved our profitability. In the past fourth quarter, amidst the most severe challenges of the past three years that the operation of many aesthetic service providers was seriously disrupted by COVID-19 pandemic, we strived to achieve quarterly revenue of RMB325.1 million, in-line with our prior guidance. In the meantime, we significantly enlarged our profit scale from the third quarter by achieving non-GAAP net income attributable to So-Young International Inc. of RMB38.8 million, thanks to the optimized cost structure and increased efficiency. As of the end of 2022, our cash balance remained at a level of nearly RMB1.6 billion, which provides us with solid financial flexibility when exploring new business growth opportunities in the year ahead. ”

 

“Looking into 2023, we will continue to scale up our existing business, leveraging the multi-year experience and insights of the industry, the loyal user base and our strong relationship with thousands of institution partners. At the same time, we will increase our investments in So-Young Prime, a one-stop aesthetic service offering endorsed by ourselves by integrating product, doctor and institution resources. We believe such product will diversify our revenue streams and it will be supported by our unique strength and as a barrier for our competitors. In summary, we are still optimistic about the long-term prospect of Chinese aesthetic sector. With the re-open of business activities in China, we expect to see a gradual recovery of consumer spending and the return of our business growth.”Mr. Jin concluded.

 

Fourth Quarter 2022 Financial Results

 

Revenues

 

Total revenues were RMB325.1 million (US$47.1 million), a decrease of 27.7% from RMB449.5 million in the same period of 2021. The decrease was primarily due to a decrease in average revenue per paying medical service provider. The decrease in average revenue per paying medical service provider was primarily due to: 1) COVID-19 control measures and the surge of COVID-19 cases, especially in major areas in China, limited people's visit to offline service providers; 2) pressure on overall Chinese consumer market.

 

·Information services and other revenues were RMB233.9 million (US$33.9 million), a decrease of 32.1% from RMB344.3 million in the same period of 2021. The decrease was primarily due to a decrease in the number of paying medical service providers subscribing to information services.

 

·Reservation services revenues were RMB26.0 million (US$3.8 million), a decrease of 37.2% from RMB41.4 million in the same period of 2021. The decrease was primarily due to COVID-19 control measures and the surge of COVID-19 cases, especially in major areas in China, limited people's visit to offline service providers.

 

·Sales of equipment and maintenance services revenues were RMB65.3 million (US$9.5 million) and RMB63.8 million in the fourth quarter of 2022 and 2021, respectively, from Wuhan Miracle Laser Systems, Inc. (“Wuhan Miracle”).

 

Cost of Revenues

 

Cost of revenues was RMB88.2 million (US$12.8 million), a decrease of 30.6% from RMB127.1 million in the fourth quarter of 2021. The decrease was primarily due to measures taken to improve cost structure. Cost of revenues included share-based compensation expenses of RMB1.0 million (US$0.1 million), compared with RMB5.8 million in the corresponding period of 2021.

 

2

 

 

Operating Expenses

 

Total operating expenses were RMB212.6 million (US$30.8 million), a decrease of 42.8% from RMB371.9 million in the fourth quarter of 2021.

 

·Sales and marketing expenses were RMB98.4 million (US$14.3 million), a decrease of 35.6% from RMB152.7 million in the fourth quarter of 2021. The decrease was primarily due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.4 million (US$0.1 million), compared with RMB3.7 million in the corresponding period of 2021.

 

·General and administrative expenses were RMB73.2 million (US$10.6 million), a decrease of 14.8% from RMB85.9 million in the fourth quarter of 2021. The change was primarily due to a decrease in share-based compensation expenses, partially offset by an increase in payroll costs and professional services fees. General and administrative expenses included share-based compensation expenses of RMB4.3 million (US$0.6 million), compared with RMB32.3 million in the corresponding period of 2021.

 

·Research and development expenses were RMB41.1 million (US$6.0 million), a decrease of 39.2% from RMB67.5 million in the fourth quarter of 2021. The decrease was primarily attributable to a decrease in payroll costs. Research and development expenses included share-based compensation expenses of RMB1.8 million (US$0.3 million), compared with RMB7.1 million in the corresponding period of 2021.

 

Income tax benefits/(expenses)

 

Income tax benefits were RMB2.4 million (US$0.4 million), compared with income tax expenses of RMB10.1 million in the same period of 2021.

 

Net income/(loss) attributable to So-Young International Inc.

 

Net income attributable to So-Young International Inc. was RMB31.3 million (US$4.5 million), compared with a net loss attributable to So-Young International Inc. of RMB27.7 million in the fourth quarter of 2021.

 

Non-GAAP net income attributable to So-Young International Inc.

 

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB38.8 million (US$5.6 million), compared with RMB62.9 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2021.

 

Basic and Diluted Earnings/(loss) per ADS

 

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.29 (US$0.04) and RMB0.29 (US$0.04), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.26 and RMB0.26, respectively, in the same period of 2021.

 

Fiscal Year 2022 Financial Results

 

Revenues

 

Total revenues were RMB1,257.9 million (US$182.4 million), a decrease of 25.7% from RMB1,692.5 million in fiscal year 2021.

 

·Information services and other revenues were RMB888.5 million (US$128.8 million), a decrease of 31.9% from RMB1,304.5 million in fiscal year 2021. The decrease was primarily due to a decrease in the number of paying medical service providers subscribing to information services.

 

·Reservation services revenues were RMB128.7 million (US$18.7 million), a decrease of 53.4% from RMB276.1 million in fiscal year 2021. The decrease was primarily due to control measures caused by the resurgence of COVID-19 in China and adoption of an operating strategy which gave higher subsidies to end users.

 

·Sales of equipment and maintenance services revenues were RMB240.7 million (US$34.9 million), from Wuhan Miracle.

 

3

 

 

Cost of Revenues

 

Cost of revenues were RMB393.3 million (US$57.0 million), an increase of 19.9% from RMB327.9 million in fiscal year 2021. The increase was primarily due to the consolidation of Wuhan Miracle. In addition, cost of revenues for fiscal year 2022 included share-based compensation expenses of RMB8.3 million (US$1.2 million) compared to RMB18.8 million in fiscal year 2021.

 

Operating Expenses

 

Total operating expenses were RMB967.4 million (US$140.3 million), a decrease of 30.8% from RMB1,397.1 million in fiscal year 2021.

 

·Sales and marketing expenses were RMB472.1 million (US$68.4 million), a decrease of 40.4% from RMB792.5 million in fiscal year 2021. The decrease was primarily due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses for fiscal year 2022 included share-based compensation expenses of RMB6.8 million (US$1.0 million), compared to RMB9.8 million in fiscal year 2021.

 

·General and administrative expenses were RMB260.2 million (US$37.7 million), an increase of 3.2% from RMB252.2 million in fiscal year 2021. The increase was primarily due to an increase in staff costs and professional services fees. General and administrative expenses for 2022 included share-based compensation expenses of RMB19.0 million (US$2.8 million), compared to RMB56.7 million in fiscal year 2021.

 

·Research and development expenses were RMB235.1 million (US$34.1 million), a decrease of 18.0% from RMB286.6 million in fiscal year 2021. The decrease was primarily attributable to a decrease in payroll costs. Research and development expenses for 2022 included share-based compensation expenses of RMB9.3 million (US$1.3 million), compared to RMB20.9 million in fiscal year 2021.

 

Income tax benefits/(expenses)

 

Income tax benefits were RMB21.0 million (US$3.0 million), compared with an income tax expense of RMB21.2 million in fiscal year 2021. The increase in income tax benefits was primarily due to the refund of income tax of RMB12.6 million in the third quarter of 2022 based on the final 2021 tax return filing result.

 

Net loss attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB65.6 million (US$9.5 million), compared with a net loss attributable to So-Young International Inc. of RMB8.4 million in fiscal year 2021.

 

Non-GAAP net (loss)/income attributable to So-Young International Inc.

 

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB139.5 million non-GAAP net income attributable to So-Young International Inc. in fiscal year 2021.

 

Basic and Diluted loss per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.61 (US$0.09) and RMB0.61 (US$0.09), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.08 and RMB0.08 in fiscal year 2021.

 

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

 

As of December 31, 2022, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,585.3 million (US$229.8 million), compared with RMB1,756.0 million as of December 31, 2021.

 

4

 

 

Business Outlook

 

For the first quarter of 2023, So-Young expects total revenues to be between RMB290 million (US$42.0 million) and RMB310 million (US$44.9 million), representing a decrease of 3.4% and an increase of 3.2% from the same period in 2022. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

 

Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and intangible assets from income/(loss) from operations and net income/(loss) attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. This is not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

 

Conference Call Information

 

So-Young's management will hold an earnings conference call on Tuesday, March 21, 2023, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 

International: +1-412-902-4272
Mainland China: 4001-201203
US: +1-888-346-8982
Hong Kong: +852-301-84992
Passcode: So-Young International Inc.

 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, March 28, 2023. The dial-in details are:

 

International: +1-412-317-0088
US: +1-877-344-7529
Passcode: 2937673

 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

 

About So-Young International Inc.

 

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

 

5

 

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to fourth parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

 

For more information, please contact:

 

So-Young

 

Investor Relations

Ms. Vivian Xu

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

 

Christensen

 

In China

Mr. Eric Yuan

Phone: +86-10-5900-1548

E-mail: eric.yuan@christensencomms.com

 

In US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

Email: linda.bergkamp@christensencomms.com

 

6

 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)

 

   As of 
   December 31,   December 31,   December 31, 
   2021   2022   2022 
   RMB   RMB   US$ 
Assets            
Current assets:               
Cash and cash equivalents   1,331,968    694,420    100,681 
Restricted cash and term deposits   15,119    14,908    2,161 
Trade receivables   54,829    36,006    5,220 
Inventories, net   91,812    120,480    17,468 
Receivables from online payment platforms   18,864    14,787    2,144 
Amounts due from related parties   14,038    33,382    4,840 
Term deposits and short-term investments   408,946    875,955    127,002 
Prepayment and other current assets   91,842    126,889    18,397 
Total current assets   2,027,418    1,916,827    277,913 
Non-current assets:               
Long-term investments   252,500    227,959    33,051 
Intangible assets   193,955    169,280    24,543 
Goodwill   540,693    540,693    78,393 
Property and equipment, net   124,576    116,184    16,845 
Deferred tax assets   47,520    64,739    9,386 
Operating lease right-of-use assets   95,609    62,898    9,119 
Other non-current assets   48,097    99,293    14,396 
Total non-current assets   1,302,950    1,281,046    185,733 
Total assets   3,330,368    3,197,873    463,646 
                
Liabilities               
Current liabilities:               
Taxes payable   48,571    74,580    10,813 
Contract liabilities   139,155    110,159    15,972 
Salary and welfare payables   103,624    72,532    10,516 
Amounts due to related parties   681    5,895    855 
Accrued expenses and other current liabilities   376,841    224,589    32,561 
Operating lease liabilities-current   43,529    50,285    7,291 
Total current liabilities   712,401    538,040    78,008 
Non-current liabilities:               
Operating lease liabilities-non current   62,356    20,972    3,041 
Deferred tax liabilities   38,577    30,993    4,494 
Total non-current liabilities   100,933    51,965    7,535 
Total liabilities   813,334    590,005    85,543 
                
Shareholders’ equity:            
Treasury stock   (217,712)   (232,835)   (33,758)
Class A Ordinary shares (US$ 0.0005 par value;  750,000,000 shares authorized as of December 31, 2021 and December 31, 2022; 71,736,059 and 69,092,367 shares issued and outstanding as of December 31, 2021, 73,065,987 and 68,843,320 shares issued and outstanding as of December 31, 2022, respectively)   230    236    33 
Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2021 and December 31, 2022; 12,000,000 shares issued and outstanding as of December 31, 2021 and December 31, 2022)   37    37    5 
Additional paid-in capital   2,999,562    3,043,971    441,334 
Statutory reserves   20,331    29,027    4,209 
Accumulated deficit   (272,368)   (346,618)   (50,255)
Accumulated other comprehensive (loss)/income   (83,891)   4,107    595 
Total So-Young International Inc. shareholders’ equity   2,446,189    2,497,925    362,163 
Non-controlling interests   70,845    109,943    15,940 
Total shareholders’ equity   2,517,034    2,607,868    378,103 
Total liabilities and shareholders’ equity   3,330,368    3,197,873    463,646 

7

 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December 31,
2021
   December 31,
2022
   December 31,
2022
   December 31,
2021
   December 31,
2022
   December 31,
2022
 
   RMB   RMB   US$   RMB   RMB   US$ 
Revenues                              
Information services and others   344,315    233,877    33,909    1,304,455    888,475    128,817 
Reservation services   41,372    25,966    3,765    276,052    128,668    18,655 
Sales of equipment and maintenance services   63,836    65,303    9,469    111,956    240,731    34,903 
Total revenues   449,523    325,146    47,143    1,692,463    1,257,874    182,375 
Cost of revenues   (127,090)   (88,202)   (12,788)   (327,889)   (393,292)   (57,022)
Gross profit   322,433    236,944    34,355    1,364,574    864,582    125,353 
Operating expenses:                              
Sales and marketing expenses   (152,656)   (98,358)   (14,261)   (792,484)   (472,092)   (68,448)
General and administrative expenses   (85,852)   (73,175)   (10,609)   (252,214)   (260,208)   (37,727)
Research and development expenses   (67,519)   (41,066)   (5,954)   (286,567)   (235,087)   (34,084)
Impairment of goodwill and intangible assets   (65,879)   -    -    (65,879)   -    - 
Total operating expenses   (371,906)   (212,599)   (30,824)   (1,397,144)   (967,387)   (140,259)
(Loss)/income from operations   (49,473)   24,345    3,531    (32,570)   (102,805)   (14,906)
Other income/(expenses):                              
Investment income, net   927    267    39    8,931    4,264    618 
Interest income   3,654    10,276    1,490    19,328    28,883    4,188 
Exchange gains/(losses)   33    23    3    (4,766)   (492)   (71)
Impairment of long-term investment   -    -    -    (17,850)   (7,945)   (1,152)
Share of losses of equity method investee   (746)   (6,215)   (901)   (1,522)   (17,223)   (2,497)
Others, net   2,208    646    94    12,044    8,246    1,196 
(Loss)/income before tax   (43,397)   29,342    4,256    (16,405)   (87,072)   (12,624)
Income tax (expenses)/benefits   (10,145)   2,423    351    (21,231)   20,965    3,040 
Net (loss)/income   (53,542)   31,765    4,607    (37,636)   (66,107)   (9,584)
Net loss/(income) attributable to noncontrolling interests   25,806    (492)   (71)   29,265    553    80 
Net (loss)/income attributable to So-Young International Inc.   (27,736)   31,273    4,536    (8,371)   (65,554)   (9,504)

 

8

 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December 31,
2021
   December 31,
2022
   December 31,
2022
   December 31,
2021
   December 31,
2022
   December 31,
2022
 
   RMB   RMB   US$   RMB   RMB   US$ 
Net (loss)/earnings per ordinary share                              
Net (loss)/earnings per ordinary share attributable to ordinary shareholder - basic   (0.34)   0.38    0.06    (0.10)   (0.79)   (0.11)
Net (loss)/earnings per ordinary share attributable to ordinary shareholder - diluted   (0.34)   0.38    0.06    (0.10)   (0.79)   (0.11)
Net (loss)/earnings per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares)   (0.26)   0.29    0.04    (0.08)   (0.61)   (0.09)
Net (loss)/earnings per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares)   (0.26)   0.29    0.04    (0.08)   (0.61)   (0.09)
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic*   81,304,182    82,925,288    82,925,288    81,680,504    82,665,269    82,665,269 
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted*   81,304,182    83,083,826    83,083,826    81,680,504    82,665,269    82,665,269 
                               
Share-based compensation expenses included in:                              
Cost of revenues   (5,830)   (979)   (142)   (18,768)   (8,282)   (1,201)
Sales and marketing expenses   (3,719)   (439)   (64)   (9,808)   (6,781)   (983)
General and administrative expenses   (32,259)   (4,337)   (629)   (56,705)   (19,021)   (2,758)
Research and development expenses   (7,106)   (1,754)   (254)   (20,869)   (9,252)   (1,341)

 

* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

9

 

 

SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and per share data)

 

    For the Three Months Ended     For the Fiscal Year Ended  
    December 31,
2021
    December 31,
2022
    December 31,
2022
    December 31,
2021
    December 31,
2022
    December 31,
2022
 
    RMB     RMB     US$     RMB     RMB     US$  
GAAP (loss)/income from operations     (49,473 )     24,345       3,531       (32,570 )     (102,805 )     (14,906 )
Add back: Share-based compensation expenses     48,914       7,509       1,089       106,150       43,336       6,283  
Add back: Impairment of goodwill and intangible assets     65,879       -       -       65,879       -       -  
Non-GAAP income/(loss) from operations     65,320       31,854       4,620       139,459       (59,469 )     (8,623 )
                                                 
GAAP net (loss)/income attributable to So-Young International Inc.     (27,736 )     31,273       4,536       (8,371 )     (65,554 )     (9,504 )
Add back: Share-based compensation expenses     48,914       7,509       1,089       106,150       43,336       6,283  
Add back: Impairment of goodwill and intangible assets attributable to So-Young International Inc.     41,748       -       -       41,748       -       -  
Non-GAAP net income/(loss) attributable to So-Young International Inc.     62,926       38,782       5,625       139,527       (22,218 )     (3,221 )

 

10